Page last updated: 2024-10-28

velnacrine and Alzheimer Disease

velnacrine has been researched along with Alzheimer Disease in 31 studies

velnacrine: RN given refers to (+-)-isomer; RN for cpd without isomeric designation not available 8/88; structure in first source; potential Alzheimer's disease drug but trial halted due to abnormal liver tests

Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Research Excerpts

ExcerptRelevanceReference
"To evaluate the long-term effectiveness and safety of an investigational cholinesterase inhibitor, that is, velnacrine maleate, in treating patients with clinically probable Alzheimer's disease (according to the criteria of the National Institute of Neurological Disorders and Stroke [Washington, DC]-Alzheimer Disease and Related Disorders Association [Chicago, Ill])."5.08Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. ( Antuono, PG, 1995)
"Patients with Alzheimer's disease received 150 mg/day and 225 mg/day Velnacrine maleate (parallel-group treatment) and placebo."2.68Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. ( Clipp, EC; Moore, MJ, 1995)
"4) Velnacrine was shown to bind to both albumin and alpha 1-acid glycoprotein, but together they did not account for total binding."2.68Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease. ( Ford, JM; Roberts, CJ; Wood, DM, 1996)
" Direct liver injury, possibly associated with the production of a toxic metabolite, would be consistent with reports of aberrant xenobiotic metabolism in Alzheimer's disease patients."2.67Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate. ( Hardiman, S; Miller, K; Murphy, M, 1993)
"Velnacrine was administered in various doses."2.67Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease. ( Cutler, NR; Murphy, MF; Nash, RJ; Sramek, JJ, 1992)
"Velnacrine was rapidly absorbed after oral administration."2.67Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease. ( Ho, I; Hsu, R; Lassman, HB; Puri, SK, 1990)
" To assess adverse events in relation to dosage and plasma drug levels, 24 hospitalized AD subjects were randomly assigned to receive placebo or HP 029 for 10 days in a double-blind, sequential escalation study."2.67Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings. ( Cutler, NR; De Luna, DM; Murphy, MF; Nash, RJ; Prior, PL, 1990)
" In this open, randomized, crossover study, 24 healthy, elderly men were given 100 mg of velnacrine on two different study days to assess the influence of food on the bioavailability of velnacrine."2.66The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent. ( Ho, I; Hsu, RS; Lassman, HB; Puri, SK, 1989)
" The mean plasma half-life was about 2."2.66Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent. ( Ho, I; Hsu, RS; Lassman, HB; Puri, SK, 1989)
"Velnacrine is a derivative of tacrine."2.42Velnacrine for Alzheimer's disease. ( Birks, J; Wilcock, GG, 2004)
" The two drugs are special as the dosage of them is guided mainly by side effects and not by therapeutic effects in contrast to most drugs used for psychiatric disorders."2.38Side effects of long acting cholinesterase inhibitors. ( Beermann, B, 1993)
"Velnacrine maleate is a novel, orally active acetylcholinesterase inhibitor of the acridine class with a longer duration of action than physostigmine."1.29Velnacrine maleate improves delayed matching performance by aged monkeys. ( Buccafusco, JJ; Jackson, WJ; Rush, DK; Terry, AV; Turk, DJ, 1995)
"The acridine-based, potential Alzheimer's disease therapeutic agents, tacrine and velnacrine, were incubated with rat or gerbil neocortical synaptosomal membranes."1.29Interaction of tacrine and velnacrine with neocortical synaptosomal membranes: relevance to Alzheimer's disease. ( Butterfield, DA; Carney, J; Hall, N; Hensley, K; Umhauer, S, 1993)

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19904 (12.90)18.7374
1990's24 (77.42)18.2507
2000's3 (9.68)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shutske, GM2
Pierrat, FA2
Kapples, KJ1
Cornfeldt, ML2
Szewczak, MR2
Huger, FP2
Bores, GM2
Haroutunian, V2
Davis, KL2
Birks, J1
Wilcock, GG1
Silva, AS1
Saldanha, C1
Martins e Silva, J1
Jackson, WJ1
Buccafusco, JJ1
Terry, AV1
Turk, DJ1
Rush, DK1
Clipp, EC2
Moore, MJ2
Antuono, PG1
al Casey, S1
Brewster, D1
Viau, C1
Acosta, D1
Schehr, RS1
Siegfried, KR1
Hardiman, S1
Miller, K1
Murphy, M2
Beermann, B1
Butterfield, DA2
Hensley, K1
Hall, N1
Umhauer, S1
Carney, J1
Cutler, NR4
Sramek, JJ3
Zemlan, FP2
Keys, M1
Richter, RW1
Strub, RL1
Pomara, N2
Citrome, L1
Wood, DM1
Ford, JM1
Roberts, CJ1
Tabarrini, O1
Cecchetti, V1
Temperini, A1
Filipponi, E1
Lamperti, MG1
Fravolini, A1
Rangachari, A1
Ebmeier, KP1
Hunter, R1
Curran, SM1
Dougal, NJ1
Murray, CL1
Wyper, DJ1
Patterson, J1
Hanson, MT1
Siegfried, K2
Goodwin, GM1
Murphy, MF3
Nash, RJ3
Deptula, D1
Singh, R1
Hardiman, ST1
Huff, FJ1
Demkovich, JJ1
Dobson, C1
Knappe, UE1
Wesnes, KA1
Simpson, PM1
White, L1
Pinker, S1
Jertz, G1
Puri, SK3
Ho, I3
Hsu, R1
Lassman, HB3
Prior, PL1
De Luna, DM1
Hsu, RS2

Reviews

3 reviews available for velnacrine and Alzheimer Disease

ArticleYear
Velnacrine for Alzheimer's disease.
    The Cochrane database of systematic reviews, 2004, Issue:2

    Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Randomized Controlled Trials as Topic; Tacrine

2004
Pharmacodynamic and early clinical studies with velnacrine.
    Acta neurologica Scandinavica. Supplementum, 1993, Volume: 149

    Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Huma

1993
Side effects of long acting cholinesterase inhibitors.
    Acta neurologica Scandinavica. Supplementum, 1993, Volume: 149

    Topics: Alzheimer Disease; Chemical and Drug Induced Liver Injury; Cholinesterase Inhibitors; Clinical Trial

1993

Trials

17 trials available for velnacrine and Alzheimer Disease

ArticleYear
Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
    Clinical pharmacology and therapeutics, 1995, Volume: 58, Issue:2

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cognition; Double-Blind Method; Female; Huma

1995
Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Archives of internal medicine, 1995, Sep-11, Volume: 155, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Double-Blin

1995
Alzheimer's disease and caregiver time.
    Lancet (London, England), 1994, Jan-22, Volume: 343, Issue:8891

    Topics: Activities of Daily Living; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Double-Blind M

1994
Pharmacodynamic and early clinical studies with velnacrine.
    Acta neurologica Scandinavica. Supplementum, 1993, Volume: 149

    Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Huma

1993
Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate.
    Acta neurologica Scandinavica. Supplementum, 1993, Volume: 149

    Topics: Age Factors; Aged; Alzheimer Disease; Chemical and Drug Induced Liver Injury; Cholinesterase Inhibit

1993
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study".
    Alzheimer disease and associated disorders, 1995,Fall, Volume: 9, Issue:3

    Topics: Alzheimer Disease; Cholinergic Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug;

1995
Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
    Life sciences, 1996, Volume: 58, Issue:21

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, D

1996
Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease.
    European journal of clinical pharmacology, 1996, Volume: 50, Issue:1-2

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Binding, Compet

1996
Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
    Journal of neural transmission (Vienna, Austria : 1996), 1996, Volume: 103, Issue:8-9

    Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; D

1996
Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease.
    Psychopharmacology, 1992, Volume: 108, Issue:1-2

    Topics: Aged; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition; Double-B

1992
Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease.
    The Annals of pharmacotherapy, 1992, Volume: 26, Issue:9

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Drug Adm

1992
Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease.
    Psychopharmacology bulletin, 1991, Volume: 27, Issue:3

    Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Hypotension

1991
Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.
    Annals of the New York Academy of Sciences, 1991, Volume: 640

    Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Drug Evaluation; Female; Humans; Male; Middle Ag

1991
Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease.
    Journal of clinical pharmacology, 1990, Volume: 30, Issue:10

    Topics: Administration, Oral; Aged; Alzheimer Disease; Drug Administration Schedule; Drug Evaluation; Half-L

1990
Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings.
    Journal of clinical pharmacology, 1990, Volume: 30, Issue:6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Aminoacridines; Double-Blind Metho

1990
The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent.
    Journal of clinical pharmacology, 1989, Volume: 29, Issue:10

    Topics: Aged; Alzheimer Disease; Aminoacridines; Biological Availability; Chromatography, High Pressure Liqu

1989
Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent.
    Journal of clinical pharmacology, 1989, Volume: 29, Issue:3

    Topics: Adult; Alzheimer Disease; Aminoacridines; Double-Blind Method; Drug Evaluation; Drug Tolerance; Huma

1989

Other Studies

12 other studies available for velnacrine and Alzheimer Disease

ArticleYear
9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics.
    Journal of medicinal chemistry, 1989, Volume: 32, Issue:8

    Topics: Alzheimer Disease; Aminoacridines; Animals; Chemical Phenomena; Chemistry; Cholinesterase Inhibitors

1989
Effects of velnacrine maleate in the leukocyte-endothelial cell interactions in rat cremaster microcirculatory network.
    Clinical hemorheology and microcirculation, 2007, Volume: 36, Issue:3

    Topics: Acetylcholine; Alzheimer Disease; Animals; Blood Pressure; Cholinesterase Inhibitors; Endothelium, V

2007
Velnacrine maleate improves delayed matching performance by aged monkeys.
    Psychopharmacology, 1995, Volume: 119, Issue:4

    Topics: Aging; Alzheimer Disease; Animals; Behavior, Animal; Cholinesterase Inhibitors; Dose-Response Relati

1995
Effect of glutathione depletion and oxidative stress on the in vitro cytotoxicity of velnacrine maleate.
    Toxicology letters, 1995, Volume: 76, Issue:3

    Topics: Alzheimer Disease; Animals; Cells, Cultured; Cholinesterase Inhibitors; Fluorescent Dyes; Formazans;

1995
Therapeutic approaches to Alzheimer's disease. An informal survey of promising drug discovery strategies.
    Bio/technology (Nature Publishing Company), 1994, Volume: 12, Issue:2

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Drug Design; Humans; Neurotrans

1994
Interaction of tacrine and velnacrine with neocortical synaptosomal membranes: relevance to Alzheimer's disease.
    Neurochemical research, 1993, Volume: 18, Issue:9

    Topics: Alzheimer Disease; Animals; Cerebral Cortex; Cholinesterase Inhibitors; Cytoskeletal Proteins; Elect

1993
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.
    European journal of clinical pharmacology, 1995, Volume: 48, Issue:6

    Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dihydropyridines; Ethics, Me

1995
Transient elevations in pancreatic enzymes in response to a cholinesterase inhibitor.
    Clinical neuropharmacology, 1995, Volume: 18, Issue:5

    Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Male; Middle Aged; Pancreas; Tacrine

1995
Velnacrine thiaanalogues as potential agents for treating Alzheimer's disease.
    Bioorganic & medicinal chemistry, 2001, Volume: 9, Issue:11

    Topics: Administration, Oral; Alzheimer Disease; Animals; Avoidance Learning; Blood Cells; Chlorine; Choline

2001
Membrane-altering effects of velnacrine and N-methylacridinium: relevance to tacrine and Alzheimer's disease.
    Biochemical and biophysical research communications, 1992, Jun-15, Volume: 185, Issue:2

    Topics: Acridines; Alzheimer Disease; Cytoskeletal Proteins; Cytoskeleton; Electron Spin Resonance Spectrosc

1992
Cholinesterase inhibition in the scopolamine model of dementia.
    Annals of the New York Academy of Sciences, 1991, Volume: 640

    Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Memory; Scopolamine; Tacrine

1991
(+/-)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity.
    Journal of medicinal chemistry, 1988, Volume: 31, Issue:7

    Topics: Alzheimer Disease; Aminoacridines; Animals; Chemical and Drug Induced Liver Injury; Chemical Phenome

1988